Abstract
Long term treatment of venous thromboembolism is essential to complete therapy of the index episode and to reduce recurrences. Vitamin K antagonists are the mainstay for the long term treatment of venous thromboembolism for the majority of the patients as they allow oral administration. Low-molecular weight heparins are recommended for the long term treatment of cancer patients. The duration of long term anticoagulation depends on the features of the index venous thromboembolism and on the presence of associated risk factors. Patients at high risk for recurrence – mainly those who suffered unprovoked venous thromboembolism and those with cancer – should be evaluated for extended anticoagulation. The risk for major bleeding complications and the inconvenience for monitoring, dose adjustment and drug-food interactions are the main constraints for indefinite anticoagulant treatment. New anticoagulants with more favourable efficacy- safety profile and reduced need for monitoring could improve the feasibility of extended anticoagulation.
Keywords: Venous thromboembolism, vein thrombosis, pulmonary embolism, anticoagulants.
Current Vascular Pharmacology
Title:Long-term Treatment of Venous Thromboembolism
Volume: 12 Issue: 3
Author(s): Cecilia Becattini and Giorgia Manina
Affiliation:
Keywords: Venous thromboembolism, vein thrombosis, pulmonary embolism, anticoagulants.
Abstract: Long term treatment of venous thromboembolism is essential to complete therapy of the index episode and to reduce recurrences. Vitamin K antagonists are the mainstay for the long term treatment of venous thromboembolism for the majority of the patients as they allow oral administration. Low-molecular weight heparins are recommended for the long term treatment of cancer patients. The duration of long term anticoagulation depends on the features of the index venous thromboembolism and on the presence of associated risk factors. Patients at high risk for recurrence – mainly those who suffered unprovoked venous thromboembolism and those with cancer – should be evaluated for extended anticoagulation. The risk for major bleeding complications and the inconvenience for monitoring, dose adjustment and drug-food interactions are the main constraints for indefinite anticoagulant treatment. New anticoagulants with more favourable efficacy- safety profile and reduced need for monitoring could improve the feasibility of extended anticoagulation.
Export Options
About this article
Cite this article as:
Becattini Cecilia and Manina Giorgia, Long-term Treatment of Venous Thromboembolism, Current Vascular Pharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/157016111203140518154040
DOI https://dx.doi.org/10.2174/157016111203140518154040 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Dysfunction, Impaired Endogenous Platelet Inhibition and Platelet Activation in Diabetes and Atherosclerosis
Current Vascular Pharmacology Theranostic Applications of Nanomaterials in the Field of Cardiovascular Diseases
Current Pharmaceutical Design Ruptured Renal Artery Aneurysm: Successful Endovascular Therapy with Stent-Graft Placement
Current Medical Imaging The Ubiquitin-Proteasome System and Proteasome Inhibitors in Central Nervous System Diseases
Cardiovascular & Hematological Disorders-Drug Targets Role of Vasa Vasorum in Arterial Disease: A Re-emerging Factor
Current Cardiology Reviews Acute Antithrombotic Treatment of Ischemic Stroke
Current Vascular Pharmacology Current Therapeutic Strategies and Future Perspectives for the Treatment of Venous Thromboembolism
Current Pharmaceutical Design Comparision of Clinical Findings with CTPA Findings in Pulmonary Embolism
Current Medical Imaging Statin Therapy
Current Pharmaceutical Design Hypercoagulability and Nephrotic Syndrome
Current Vascular Pharmacology Current Status of Hormone Replacement Therapy in Post Menopausal Women
Current Drug Therapy Recent Advances in the Discovery of Tissue Factor/Factor VIIa Inhibitors and Dual Inhibitors of Factor VIIa/Factor Xa
Current Pharmaceutical Design Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Metallocarboxypeptidases and their Inhibitors: Recent Developments in Biomedically Relevant Protein and Organic Ligands
Current Medicinal Chemistry Homocystinuric Patient with Deficient CBS Activity: Pyridoxine Efficacy and Toxicity?
Letters in Drug Design & Discovery Subject Index To Volume 12
Current Pharmaceutical Design MRI Evaluation of Treatment Response for Local Therapies for Malignant Liver Lesions
Current Cancer Therapy Reviews Heart Failure in East Asia
Current Cardiology Reviews Portal Vein Embolization: A Preoperative Approach to Improve the Safety of Major Hepatic Resection
Current Medical Imaging Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry